Clinical trials
Unresectable Urothelial Carcinoma clinical trials
Below are recruiting unresectable urothelial carcinoma clinical trials, each written for real people, not researchers. We’re tracking 41 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07869836RecruitingPhase 3
Comparing new drug to standard chemo for advanced bladder cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
Macon, GeorgiaAges 18 years+ - NCT07815665RecruitingPhase 2/Phase 3
Ivonescimab plus enfortumab vedotin for advanced bladder cancer
This study compares two drug combinations for advanced bladder cancer that has spread or cannot be removed with surgery. The drugs aim to help the immune system fight the cancer more effectively.
Phoenix, ArizonaAges 18 years+ - NCT07667335RecruitingPhase 1/Phase 2
Combination therapy for advanced bladder cancer
This trial tests a combination of three drugs for advanced bladder cancer (including cancer of the renal pelvis or ureter) that has not been treated before. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT07241793RecruitingPhase 2
Trastuzumab rezetecan with or without immunotherapy for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07221942RecruitingPhase 2
Pembrolizumab and Enfortumab Vedotin for Advanced Bladder Cancer
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT06639347RecruitingPhase 1/Phase 2
Testing SHR-A2102 for advanced bladder cancer
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT06738251RecruitingPhase 3
Study of SHR-A2102 for advanced bladder cancer
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT06857175RecruitingPhase 3
Comparing a new drug to standard chemo for advanced bladder cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07393542RecruitingPhase 3
Combination treatment for advanced bladder cancer
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07321210Recruiting
Lymph node surgery for high-risk upper tract cancer
This trial compares removing the kidney and ureter alone versus also removing nearby lymph nodes for high-risk upper tract urothelial cancer. It aims to see if the extra step helps improve outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Anchorage, AlaskaAges 18 years+
Hear when a new Unresectable Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Unresectable Urothelial Carcinoma trials by city
Studies with a site in or near these metro areas.
Unresectable Urothelial Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for unresectable urothelial carcinoma?
- Yes. Clin2 currently lists 41 recruiting unresectable urothelial carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable urothelial carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.